Download original image
Fig. 1. The mGluR5 antagonist MPEP, but not the mGluR1 antagonist LY367385, inhibits 0.1 mM [Mg2+]o-induced [Ca2+]i spikes. (A) 0.1 mM [Mg2+]o induced synchronized and repetitive [Ca2+]i spikes within 30 sec at day 11.5. (B) LY367385 (100 µM) did not inhibit 0.1 mM [Mg2+]o-induced [Ca2+]i responses. (C) MPEP (25 µM) inhibited 0.1 mM [Mg2+]o-induced [Ca2+]i spikes. (D, E) Graph summarizing the frequency (D) and the area under the curve (E) of 0.1 mM [Mg2+]o-induced [Ca2+]i spikes in non-treated (control, n = 28), MPEP-treated (n = 21), and LY367385-treated (n = 27) cells. Relative spike frequencies or area under curves (2nd /1st: drug or non-treatment; 3rd / 1st: 0.1 mM [Mg2+]o wash) were shown as a ratio of an initial [Ca2+]i spike frequency and area under curves for 1st 0.1 mM [Mg2+]o treatment. The frequency and the area under the curve of [Ca2+]i spikes were calculated from data collected during a 10 min window before application of drug or vehicle (1st), a 10 min window at 5 min after application of drug or vehicle (2nd), and a 10 min window at 5 min after wash (3rd). Data are expressed as means ± SEM. mGluR, metabotropic glutamate receptor; MPEP, 6-Methyl-2-(phenylethynyl) pyridine. **p < 0.01 relative to respective control and LY367385 (ANOVA with Bonferroni test).
Korean J Physiol Pharmacol 2022;26:531-540 https://doi.org/10.4196/kjpp.2022.26.6.531
© Korean J Physiol Pharmacol